Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2018
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Pharmacodynamics
- Sponsors Valneva
- 17 Dec 2018 Status changed from not yet recruiting to recruiting, according to a Valneva media release.
- 06 Dec 2018 Status changed from planning to not yet recruiting.
- 02 Aug 2018 According to a Valneva media release, based on the positive outcomes of the phase 1 meeting with the FDA, the company has expected to enrol 800 adult patients in 10 USA and Europe sites.